{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-007878","form_type":"8-K","ticker":"FBIO","cik":"0001429260","company_name":"Fortress Biotech, Inc.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.270697+00:00","generated_at":"2026-05-21T04:47:51.869032+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Fortress Biotech Q1 net loss narrows to $12.7M; Checkpoint acquisition on track","bullets":["Consolidated net loss $12.7M ($0.48/sh) vs $17.9M ($1.04/sh) in Q1 2024.","Cash $91.3M as of March 31, 2025, up $34.0M from Dec 2024; Checkpoint holds $33.0M.","Emrosi launched in March 2025; first prescriptions filled for inflammatory rosacea lesions.","Checkpoint to be acquired by Sun Pharma for $4.10/sh plus $0.70 CVR; Fortress expects ~$28M at closing.","CUTX-101 NDA priority review with PDUFA Sept 30, 2025; Cyprium retains 100% of any PRV."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-007878","json":"https://secwatch.observer/filing/0001558370-25-007878.json","markdown":"https://secwatch.observer/filing/0001558370-25-007878.md","text":"https://secwatch.observer/filing/0001558370-25-007878.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1429260/000155837025007878/0001558370-25-007878-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1429260/000155837025007878/fbio-20250515x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T04:47:51.869032+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}